
EnBiotix
EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
* | N/A | $3.5m | Early VC |
Total Funding | 000k |
Related Content
EnBiotix is a biotechnology company specializing in the development of advanced synthetic biology solutions aimed at creating next-generation diagnostics and therapeutics. The company operates in the healthcare and pharmaceutical markets, serving clients that include biotech firms, pharmaceutical companies, and medical device manufacturers. EnBiotix's business model revolves around leveraging cutting-edge synthetic biology techniques to develop proprietary technologies, which are then licensed to other companies or used to create new products. Revenue is generated through licensing fees, partnerships, and direct sales of their innovative solutions. The company is led by Dr. Jim Collins, a pioneer in synthetic biology, whose patented technologies have been licensed by over 25 companies. EnBiotix is committed to pushing the boundaries of medical science to improve patient outcomes and address unmet medical needs.
Keywords: synthetic biology, diagnostics, therapeutics, biotechnology, healthcare, pharmaceutical, medical devices, innovation, licensing, partnerships.